Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome
Source abstract
Abstract
Abstract Antibiotic‐resistant pathogens are a global health challenge, necessitating innovative solutions beyond conventional antibiotics. This study introduces biomimetic nanocarriers ‐ hybrids of bacteriomimetic liposomes and biocompatible Myxobacteria outer‐membrane vesicles (OMVs) ‐ as tunable platforms for targeted antibiotic delivery. Comparative analyses of their physicochemical properties and interactions with immune cells, intestinal epithelium, and biofilm‐forming pathogens reveal distinct advantages. Hybrids excel at delivering antibiotics to intracellular targets, while Myxobacteria OMVs, particularly those of strain SBSr 073, evade immune clearance and prolong extracellular drug exposure. To support clinical translation, this study optimizes antibiotic encapsulation methods for SBSr 073 OMVs and evaluates the short‐ and long‐term impact of Cystobacter ferrugineus 23 strain OMVs on the gut microbiome in mice. Summing up, this study highlights the promise of Myxobacteria OMVs and their biomimetic hybrids as versatile tools for treating Gram‐negative biofilm‐forming pathogens. These findings underscore the potential of bioengineered and biomimetic drug carriers for combating antimicrobial resistance and pave the way for their translation toward difficult‐to‐treat infections.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bacteriophages and microbial interactions · Bacterial biofilms and quorum sensing · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Faculty of Science Department of Biology Pharmaceutical Biology Staudtstr. 5 91058 Erlangen Germany
INM‐Leibniz‐Institute for New Materials 66123 Saarbrücken Germany
Institute for Physical Process Technology Saarland University of Applied Sciences Göbenstr. 40 66117 Saarbrücken Germany
Department of Internal Medicine 3 Rheumatology and Immunology Friedrich‐Alexander‐Universiät Erlangen‐Nürnberg (FAU) and Universitätsklinikum Erlangen 91054 Erlangen Germany
Deutsches Zentrum Immuntherapie (DZI) Friedrich‐Alexander‐University Erlangen‐Nürnberg (FAU) and Universitätsklinikum Erlangen 91054 Erlangen Germany
Max Planck Institute for the Science of Light 91058 Erlangen Germany
Max‐Planck‐Zentrum für Physik und Medizin 91054 Erlangen Germany
Institute of Pharmaceutical Biology and Phytochemistry University of Münster 48149 Münster Germany
Department of Physics Friedrich‐Alexander‐Universität Erlangen‐Nürnberg 91058 Erlangen Germany
Institute of Virology University of Münster 48149 Münster Germany
FAU NeW Friedrich‐Alexander‐Universität Erlangen‐Nürnberg 91058 Erlangen Germany
Funding
Bundesministerium für Bildung und Forschung · H2020 European Research Council
References (89)
Show source-provided references
1. 10.1038/s41579-019-0293-310.1038/s41579-019-0293-3 ↗
2. 10.1016/S0140-6736(24)01867-110.1016/S0140-6736(24)01867-1 ↗
3. 2022
4. 10.1016/S1473-3099(17)30753-310.1016/S1473-3099(17)30753-3 ↗
5. 10.1038/s41522-021-00251-210.1038/s41522-021-00251-2 ↗
6. 10.1038/s41522-021-00243-210.1038/s41522-021-00243-2 ↗
7. 10.1016/j.jconrel.2019.02.03910.1016/j.jconrel.2019.02.039 ↗
8. 10.1038/s41598-023-40653-010.1038/s41598-023-40653-0 ↗
9. 10.1002/adfm.20210359110.1002/adfm.202103591 ↗
10. 10.3390/pharmaceutics802001810.3390/pharmaceutics8020018 ↗
11. 10.3390/pharmaceutics1401000410.3390/pharmaceutics14010004 ↗
12. 10.1016/j.addr.2021.03.01210.1016/j.addr.2021.03.012 ↗
13. 10.1002/anie.20140996410.1002/anie.201409964 ↗
14. 10.1021/jacs.2c0881610.1021/jacs.2c08816 ↗
15. 10.1039/D2NR02743G10.1039/D2NR02743G ↗
16. 10.3390/cells901019410.3390/cells9010194 ↗
17. 10.1039/D1NR02583J10.1039/D1NR02583J ↗
18. 10.1016/j.addr.2021.03.02010.1016/j.addr.2021.03.020 ↗
19. 10.1016/j.tips.2024.02.00610.1016/j.tips.2024.02.006 ↗
20. 10.1038/s41467-023-43914-810.1038/s41467-023-43914-8 ↗
21. 10.1038/s12276-024-01201-610.1038/s12276-024-01201-6 ↗
22. 10.1021/acsabm.3c0082210.1021/acsabm.3c00822 ↗
23. 10.1021/acs.chemmater.2c0370510.1021/acs.chemmater.2c03705 ↗
24. 10.1021/acs.nanolett.1c0248210.1021/acs.nanolett.1c02482 ↗
25. 10.1002/smll.20220747910.1002/smll.202207479 ↗
26. 10.1002/jev2.1240410.1002/jev2.12404 ↗
27. 10.3390/pharmaceutics1403054310.3390/pharmaceutics14030543 ↗
28. 10.1038/srep3081510.1038/srep30815 ↗
29. 10.1128/iai.00046-2310.1128/iai.00046-23 ↗
30. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
31. 10.3390/pharmaceutics1402026710.3390/pharmaceutics14020267 ↗
32. 10.1128/AEM.01941-1410.1128/AEM.01941-14 ↗
33. 10.1016/j.mtbio.2023.10084510.1016/j.mtbio.2023.100845 ↗
34. S. M.Collins Ph.D. Thesis Lehigh University (Bethlehem PA USA)2021.
35. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
36. 10.1002/jev2.1234810.1002/jev2.12348 ↗
37. 10.1002/anbr.20200009810.1002/anbr.202000098 ↗
38. 10.1021/acsestengg.4c0011110.1021/acsestengg.4c00111 ↗
39. 10.1016/j.biomaterials.2022.12187910.1016/j.biomaterials.2022.121879 ↗
40. 10.1038/s41467-020-16772-x10.1038/s41467-020-16772-x ↗
41. 10.1021/acsnano.9b0392410.1021/acsnano.9b03924 ↗
42. 10.1038/s41467-017-02588-910.1038/s41467-017-02588-9 ↗
43. 10.1038/s41598-023-45498-110.1038/s41598-023-45498-1 ↗
44. 10.1038/s42003-018-0027-510.1038/s42003-018-0027-5 ↗
45. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
46. 10.1016/j.jconrel.2018.09.03010.1016/j.jconrel.2018.09.030 ↗
47. 10.1074/jbc.M110.19420910.1074/jbc.M110.194209 ↗
48. 10.1038/nri383710.1038/nri3837 ↗
49. 10.3389/fimmu.2017.0101710.3389/fimmu.2017.01017 ↗
50. 10.1016/j.tcb.2020.09.00410.1016/j.tcb.2020.09.004 ↗
51. 10.1007/s00018-019-03113-510.1007/s00018-019-03113-5 ↗
52. 10.1371/journal.ppat.100676010.1371/journal.ppat.1006760 ↗
53. Balasubramanian K. · Sci Signal · 2015 · 8
54. 10.3390/ijms23191176310.3390/ijms231911763 ↗
55. 10.1007/s10517-016-3247-z10.1007/s10517-016-3247-z ↗
56. 10.1128/mBio.00534-2110.1128/mBio.00534-21 ↗
57. 10.1371/journal.pone.016037410.1371/journal.pone.0160374 ↗
58. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
59. 10.1021/acsnano.3c0240310.1021/acsnano.3c02403 ↗
60. 10.1167/iovs.61.3.2910.1167/iovs.61.3.29 ↗
61. 10.3390/pharmaceutics1505149710.3390/pharmaceutics15051497 ↗
62. 10.1155/2014/21849310.1155/2014/218493 ↗
63. 10.1016/j.ijpara.2022.04.00410.1016/j.ijpara.2022.04.004 ↗
64. 10.3389/fpubh.2022.102563310.3389/fpubh.2022.1025633 ↗
65. 10.1038/s41579-019-0294-210.1038/s41579-019-0294-2 ↗
66. K.Cirnski Ph.D. Thesis Saarland University (Saarbrücken Germany)2021.
67. 10.3390/microorganisms1106161410.3390/microorganisms11061614 ↗
68. 10.1002/cyto.a.2006910.1002/cyto.a.20069 ↗
69. 10.1038/s41392-022-00974-410.1038/s41392-022-00974-4 ↗
70. 10.1021/acsinfecdis.1c0008110.1021/acsinfecdis.1c00081 ↗
71. 10.3389/fmicb.2019.0088710.3389/fmicb.2019.00887 ↗
72. 10.3390/nu1205147410.3390/nu12051474 ↗
73. 10.3390/microorganisms811171510.3390/microorganisms8111715 ↗
74. 10.1038/s41522-020-00160-w10.1038/s41522-020-00160-w ↗
75. 10.3389/fnut.2020.61287510.3389/fnut.2020.612875 ↗
76. 10.1080/19490976.2024.240637910.1080/19490976.2024.2406379 ↗
77. 10.1038/s41467-023-39403-710.1038/s41467-023-39403-7 ↗
78. 10.3389/fphar.2023.120308710.3389/fphar.2023.1203087 ↗
79. 10.1128/iai.00322-2310.1128/iai.00322-23 ↗
80. 10.1038/s41467-020-18871-110.1038/s41467-020-18871-1 ↗
81. 10.1007/978-3-031-21391-5_910.1007/978-3-031-21391-5_9 ↗
82. 10.1016/j.bioactmat.2021.02.01410.1016/j.bioactmat.2021.02.014 ↗
83. 10.1038/s41592-022-01460-z10.1038/s41592-022-01460-z ↗
84. 10.1021/acsnano.4c0439610.1021/acsnano.4c04396 ↗
85. 10.1038/s41596-021-00515-310.1038/s41596-021-00515-3 ↗
86. 10.1211/jpp.60.1.000810.1211/jpp.60.1.0008 ↗
87. 10.1073/pnas.100008010710.1073/pnas.1000080107 ↗
88. 10.1089/omi.2011.011810.1089/omi.2011.0118 ↗
89. 10.1016/j.cell.2020.02.03510.1016/j.cell.2020.02.035 ↗